SABS SAB Biotherapeutics Inc

Price (delayed)

$3.465

Market cap

$264.95M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.45

Enterprise value

$250.6M

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 69
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 28
Highlights
The EPS has soared by 61% YoY
SAB Biotherapeutics's equity has surged by 50% QoQ
SAB Biotherapeutics's net income has shrunk by 103% QoQ but it has surged by 99% YoY
The company's debt fell by 9% YoY but it rose by 3.7% QoQ
SAB Biotherapeutics's revenue has shrunk by 100% YoY
SAB Biotherapeutics's gross profit has shrunk by 100% YoY

Key stats

What are the main financial stats of SABS

SABS stock price

How has the SAB Biotherapeutics stock price performed over time
Intraday
3.13%
1 week
-2.94%
1 month
-6.1%
1 year
85.54%
YTD
-7.35%
QTD
-9.53%

Financial performance

How have SAB Biotherapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$58.18M
Net income
-$398,429
Gross margin
N/A
Net margin
N/A
SAB Biotherapeutics's net income has shrunk by 103% QoQ but it has surged by 99% YoY
SAB Biotherapeutics's revenue has shrunk by 100% YoY
SAB Biotherapeutics's gross profit has shrunk by 100% YoY
SABS's operating income is down by 38% YoY and by 19% from the previous quarter

Price vs fundamentals

How does SABS's price correlate with its fundamentals

Growth

What is SAB Biotherapeutics's growth rate over time

Valuation

What is SAB Biotherapeutics stock price valuation
P/E
N/A
P/B
0.78
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
86.67
EV/Sales
N/A
The EPS has soared by 61% YoY
The P/B is 67% below the 5-year quarterly average of 2.3 and 17% below the last 4 quarters average of 0.9
SAB Biotherapeutics's equity has surged by 50% QoQ
SAB Biotherapeutics's revenue has shrunk by 100% YoY

Efficiency

How efficient is SAB Biotherapeutics business performance
SABS's ROA has plunged by 102% from the previous quarter but it has soared by 100% YoY
The ROE has plunged by 102% from the previous quarter but it has soared by 100% YoY
SAB Biotherapeutics's ROIC has plunged by 101% from the previous quarter but it has soared by 100% YoY

Dividends

What is SABS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SABS.

Financial health

How did SAB Biotherapeutics financials performed over time
The company's total assets rose by 44% QoQ
The total liabilities rose by 27% year-on-year
The company's debt is 97% lower than its equity
SABS's debt to equity has dropped by 91% year-on-year and by 25% since the previous quarter
SAB Biotherapeutics's equity has surged by 50% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.